The PORTuguese Registry of Supera Supported Femoral-Fopliteal Revascularization (SupPORT Registry)

Ki vehet részt

• Evidence of symptomatic obstructive peripheral arterial disease
• All-comer patients undergoing endovascular lower-limb revascularization with Supera® stent implantation in the superficial femoral (SFA) or popliteal arteries
• Patient or legal representative understand the SupPORT registry procedures, and have voluntarily provided informed written consent regarding their participation
• Participant is willing to remain in the SupPORT Registry for at least 1 year
• Target lesion is a primary atherosclerotic lesion or a restenosis occurring in a non-stented of the SFA or the popliteal artery, distancing at least ≥ 1 cm from any previously implanted vascular stent
• Target lesion causes a ≥50% arterial obstruction (visually confirmed on digital subtraction angiography)

Ki nem vehet részt

• • Any contraindication for peri-interventional or post-interventional anti-thrombotic therapy (including, but not restricted to Non-fractioned heparina, low-molecular weight heparina [LMWH], Clopidogrel, Ticagrelol, Ticlopidine, Acetylsalicylic acid, dipiridamol, direct thrombin [factor II] or factor Xa inhibitors, vitamin-K antagonists)
• Treatment of intrastent restenosis/occlusion of previous peripheral vascular stent
• Non-corrected hemodynamically significant obstructive arterial disease of the ipsilateral inflow arteries (aorta, iliac arteries)
• Participation in other research study that may influence obtained results
• Pregnant or breastfeeding women, or expected pregnancy to occur during the study period